Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Competitive

Signal category

Competitive Signals

Monitor how competitors respond to market openings, data releases, and regulatory milestones across key franchises.

Pipeline moves, positioning shifts, and competitive dynamics that change how assets are valued and prioritized.

Competitive LandscapeCMP
DrugMOA / CompanyStage
AllerganNovartisLead

Focal Asset

Allergan

Company

Novartis

Indication

Ophthalmology / Ocular Inflammation

Signal Score

8.4

Competitivehigh signal

Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

The Pra-ffd hydrogel demonstrated improved bioavailability and reduced ocular inflammation in preclinical models.

June 17, 2026Read signal →
Competitive LandscapeCMP
DrugMOA / CompanyStage
HyperlipidemiaMerckLead

Focal Asset

Hyperlipidemia

Company

Merck

Indication

Cardiovascular / PCSK9 Inhibition

Competitive LandscapeCMP
DrugMOA / CompanyStage
HepatologyRocheLead

Focal Asset

Hepatology

Company

Roche

Indication

Hepatology / Chronic Liver Disease

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

Signal Score

8.4

Competitivehigh signal

Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate

Merck has published a method for the large-scale synthesis of enlicitide decanoate, an investigational oral PCSK9 inhibitor.

June 16, 2026Read signal →

Signal Score

8.4

Competitivehigh signal

Roche Launches Liver Disease Panel to Enhance Chronic Liver Disease Management

Roche has launched the Liver Disease Panel, a suite of certified algorithms aimed at improving the management of chronic liver disease (CLD). This panel includes the LiverPRO algorithm, which facilitates early detection of liver fibrosis using routine blood markers.

June 16, 2026Read signal →